Investigational drug · Phase 3
GR1803
Also called: Velinotamig specified specified days., CLN-803
Not approved by FDA. In 7 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Multiple Myeloma, Immune Thrombocytopenia (ITP), Warm Autoimmune Hemolytic Anemia (WAIHA).
Phase 3Last checked: Nov 19, 2026Latest source record: Jul 31, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
7
6 still active
All registered trials
7
Any phase or sponsor naming "GR1803"
First trial start
2022
May 27, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "GR1803", any sponsor or status.
Conditions studied
As listed on its trial records.
- Multiple Myeloma
- Immune Thrombocytopenia (ITP)
- Warm Autoimmune Hemolytic Anemia (WAIHA)
- Multiple Myleoma
- Systemic Lupus Erthematosus
- Auto Immune Disease
- Multiple Myeloma (MM)
Approved drugs for the same conditions: Multiple myeloma · Anemia · Immune thrombocytopenia · Hematology and blood cancers · Cardiovascular and metabolic · Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "GR1803" as an intervention, largest first.
- A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple MyelomaPivotal-lookingRecruiting
Genrix (Shanghai) Biopharmaceutical Co., Ltd.Industry
NCT07452198 · 358 participants (planned) · Start Mar 9, 2026 · Primary completion Mar 2029
Drug: GR1803 injection; Daratumumab and 2 more · For: Multiple Myeloma
Sites: Tianjin, China
- GR1803 Injection in Patients With Relapsed/Refractory Multiple MyelomaActive, not recruiting
Genrix (Shanghai) Biopharmaceutical Co., Ltd.Industry
NCT06566547 · 116 participants (planned) · Start Aug 26, 2024 · Primary completion May 12, 2027
Drug: GR1803 injection · For: Multiple Myeloma
Sites: Hangzhou, China
Genrix (Shanghai) Biopharmaceutical Co., Ltd.Industry
NCT07102706 · 76 participants · Start May 27, 2022 · Primary completion May 20, 2025
Drug: GR1803 injection · For: Multiple Myeloma (MM)
Sites: Hangzhou, China
- A Phase 1b/2a Study of Velinotamig in Adults With Relapsed/Refractory ITP and wAIHANot yet recruiting
Cullinan Therapeutics Inc.Industry
NCT07738822 · 72 participants (planned) · Start Dec 2026 · Primary completion Jan 2029
Drug: Velinotamig specified dose on specified days. · For: Immune Thrombocytopenia (ITP); Warm Autoimmune Hemolytic Anemia (WAIHA)
Sites: Webster, Texas
Genrix (Shanghai) Biopharmaceutical Co., Ltd.Industry
NCT07348055 · 44 participants (planned) · Start Feb 2, 2026 · Primary completion Jun 1, 2027
Drug: GR1803 injection · For: Systemic Lupus Erthematosus; Auto Immune Disease
Sites: Wuhan, China
- A Study of GR1803 Injection in Combination With Anti-CD38 Monoclonal Antibody for the Treatment of Participants With Multiple MyelomaNot yet recruiting
Genrix (Shanghai) Biopharmaceutical Co., Ltd.Industry
NCT07090954 · 32 participants (planned) · Start Aug 31, 2025 · Primary completion Jul 31, 2026
Drug: GR1803 injection; Anti-CD38 Monoclonal Antibody · For: Multiple Myeloma
Sites: Shanghai, China; Xi'an, China
- GR1803 Injection in Patients With RRMMRecruiting
Genrix (Shanghai) Biopharmaceutical Co., Ltd.Industry
NCT06952075 · 30 participants (planned) · Start Apr 24, 2025 · Primary completion Jul 1, 2027
Drug: GR1803 · For: Multiple Myleoma
Sites: Tianjin, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Multiple Myeloma
- EtentamigABBV-383, TNB-383BPhase 38 trials
AbbVie · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma, Amyloid Light Chain (AL) Amyloidosis
- BMS-986348CC-92480, mezigdomidePhase 37 trials
Bristol Myers Squibb · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma
- JNJ-79635322Ramantamig, BCMAxGPRC5DxCD3Phase 37 trials
Johnson & Johnson (Janssen) · Multiple Myeloma
- Cilta-celJNJ-68284528Phase 36 trials
Johnson & Johnson (Janssen) · Multiple Myeloma
- Anitocabtagene AutoleucelCART-ddBCMAPhase 34 trials
Gilead Sciences · Multiple Myeloma, Newly Diagnosed Multiple Myeloma
- CevostamabRO7187797Phase 34 trials
Roche (Genentech) · Multiple Myeloma
- IBI3003Phase 34 trials
Innovent Biologics (Suzhou) Co. Ltd. · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma
- Arlocabtagene AutoleucelBMS-986393, GPRC5D CAR T cellsPhase 32 trials
Bristol Myers Squibb · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma (RRMM)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.